ZVRA · Zevra Therapeutics, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 28, 2020; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net income non-GAAP | $15.2M | Q2 2026 | — |
|
|
|||
| Adjusted net income per diluted share non-GAAP | $0.25 | Q2 2026 | — |
|
|
|||
| DiSCOVER Phase 3 trial enrolled patients | 66 | through Q2 2026 | — |
|
|
|||
| Fully diluted common shares | 69,298,105 | as of June 30, 2026 | — |
| Global Expanded Access Program (EAP) enrolled patients | 132 | as of June 30, 2026 | — |
| Market access | 69% | Q2 2026 | — |
|
|
|||
| MIPLYFFA prescription enrollment forms | 14 | Q2 2026 | — |
| MIPLYFFA prescription enrollment forms since product launch | 184 | through Q2 2026 | — |
| Total shares of common stock outstanding | 59,341,906 | as of June 30, 2026 | — |
| MIPLYFFA prescription enrollment forms (since product launch, total) | 170 | since product launch through Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZVRA
this stock
Zevra Therapeutics, Inc.
|
$686.48M | +26.3% | +350.9% | 12.3 | 12.0% |
|
ONC
BeOne Medicines Ltd.
|
$530.72B | +14.4% | +22179.2% | 816.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.25B | +11.6% | +46.2% | 30.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.16B | +4.1% | +20.8% | 19.8 | 3.3% |
|
ARGX
Argenx SE
|
$52.69B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 28, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZVRA | -2.1% | -11.4% | +30.1% | +19.0% | +26.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -2.5% | -15.8% | +16.3% | +15.1% | +12.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.